Evidence map›Paper›PMID 27806571›Full record

ArticleBiochemistry2016

Knockout of the Ribonuclease Inhibitor Gene Leaves Human Cells Vulnerable to Secretory Ribonucleases.

Sydney P Thomas, Eunji Kim, Jin-Soo Kim, Ronald T Raines

Abstract read
In one paragraph

Article in Biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Novel Organomineral Complex with Prolonged Antitumor Action.International journal of molecular sciences · 2025
    Article
  3. Article
  4. Article
  5. Heat Shock Protein 90's Mechanistic Role in Contact Hypersensitivity.Journal of immunology (Baltimore, Md. : 1950) · 2022
    Article
  6. Emerging biological functions of ribonuclease 1 and angiogenin.Critical reviews in biochemistry and molecular biology · 2022
    Review
  7. Article
  8. Article
  9. Semisynthesis of Human Ribonuclease-S.Bioconjugate chemistry · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Sydney P ThomasGraduate Program in Cellular & Molecular Biology, University of Wisconsin-Madison , 1525 Linden Drive, Madison, Wisconsin 53706, United States.
Eunji KimCenter for Genome Engineering, Institute for Basic Science , Seoul 08826, Republic of Korea.
Jin-Soo KimCenter for Genome Engineering, Institute for Basic Science , Seoul 08826, Republic of Korea.
Ronald T RainesDepartment of Biochemistry, University of Wisconsin-Madison , 433 Babcock Drive, Madison, Wisconsin 53706, United States.
Institute for Basic Science · KRUniversity of Wisconsin–Madison · US

Funding

RIBONUCLEASES IN CANCER THERAPYR01CA073808 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI RAINES, RONALD T · 1997 to 2024
$7.3M
NCI NIH HHS R01 CA073808
6 · The paper itself

Abstract

Ribonuclease inhibitor (RNH1) is a cytosolic protein that binds with femtomolar affinity to human ribonuclease 1 (RNase 1) and homologous secretory ribonucleases. RNH1 contains 32 cysteine residues and has been implicated as an antioxidant. Here, we use CRISPR-Cas9 to knock out RNH1 in HeLa cells. We find that cellular RNH1 affords marked protection from the lethal ribonucleolytic activity of RNase 1 but not from oxidants. We conclude that RNH1 protects cytosolic RNA from invading ribonucleases.

Indexed as

Carrier ProteinsCell ProliferationCell SurvivalCRISPR-Cas SystemsDose-Response Relationship, DrugHeLa CellsHumansHydrogen PeroxideOxidantsRibonuclease, PancreaticRNA, NeoplasmCarrier ProteinsHydrogen PeroxideOxidantsRibonuclease, PancreaticRNA, NeoplasmRNH1 protein, human

Identifiers

PMID27806571
PMCPMC5148631
OpenAlexW2547372962

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.